INVESTIGADORES
OLIVERI Maria Beatriz
artículos
Título:
Intravenous pamidronate treatment and pregnancy: its effect on mother and infant bone health
Autor/es:
MASTAGLIA SR; WATMAN N; OLIVERI B,
Revista:
OSTEOPOROSIS INTERNATIONAL
Editorial:
SPRINGER LONDON LTD
Referencias:
Lugar: London; Año: 2010 vol. 21 p. 1959 - 1962
ISSN:
0937-941X
Resumen:
Abstract
Introduction Type 1 Gaucher's disease (GD1) is a lysosomal
storage disorder associated with disabling bone
involvement. The choice treatment for Gaucher's disease
is enzyme replacement therapy (ERT). The use of
bisphosphonate treatment for osteopenia and osteoporosis
has been suggested.Type 1 Gaucher's disease (GD1) is a lysosomal
storage disorder associated with disabling bone
involvement. The choice treatment for Gaucher's disease
is enzyme replacement therapy (ERT). The use of
bisphosphonate treatment for osteopenia and osteoporosis
has been suggested.
Case A 22-year-old woman diagnosed with GD1 had
received ERT intermittently, depending on availability of
the enzyme since the enzyme was not always available.
Due to severe bone involvement and multiple vertebral
fractures, intravenous administration of 60 mg of pamidronate
every 3 months and safe contraception were
indicated. Fifteen days after receiving the fourth infusion,
the patient informed us she was pregnant. A baby girl was
born by cesarean delivery at week 37, showing no evidence
of skeletal abnormality or clinical signs of hypocalcemia.
The baby developed normally, presenting no significant
pathology. At present (age 15 months), height, body
weight, and bone mineral density by DXA are within
normal range. The mother showed stable total skeleton and
right femoral neck bone mineral density (BMD) values, no
new fractures, and only ~3% decrease in lumbar spine
BMD 15 months post-delivery and after a 1 year breastfeeding
period (expected average ~78%).A 22-year-old woman diagnosed with GD1 had
received ERT intermittently, depending on availability of
the enzyme since the enzyme was not always available.
Due to severe bone involvement and multiple vertebral
fractures, intravenous administration of 60 mg of pamidronate
every 3 months and safe contraception were
indicated. Fifteen days after receiving the fourth infusion,
the patient informed us she was pregnant. A baby girl was
born by cesarean delivery at week 37, showing no evidence
of skeletal abnormality or clinical signs of hypocalcemia.
The baby developed normally, presenting no significant
pathology. At present (age 15 months), height, body
weight, and bone mineral density by DXA are within
normal range. The mother showed stable total skeleton and
right femoral neck bone mineral density (BMD) values, no
new fractures, and only ~3% decrease in lumbar spine
BMD 15 months post-delivery and after a 1 year breastfeeding
period (expected average ~78%).8%).
Conclusion It could be posited that pamidronate exerted a
positive protective effect on the mother's skeleton with no
evidence of adverse effects on pregnancy or on the baby's
health to date.It could be posited that pamidronate exerted a
positive protective effect on the mother's skeleton with no
evidence of adverse effects on pregnancy or on the baby's
health to date.